7 A-share listed pharmaceutical companies with a market value of more than 100 billion yuan, "pharma one brother" status or change?

Pharmaceutical Network Market Analysis) Recently, the news that Stone Pharmaceutical Group will go to Science and Technology Board has aroused high concern and discussion in the industryAt the same time, Stone Pharmaceuticals also reported first-quarter results for 2020In the first quarter, the company achieved revenue of RMB6.125 billion, up 11.5% YoY, and net profit attributable to shareholders was RMB1,159 million, up 21.8% YoYthe industry's comprehensive stone medicine data, think that if the stone pharmaceutical group can successfully listed in the Science and Technology Board, its market value is expected to greatly exceed Huaxi BioIn addition, if the stone medicine into the entire A-share market pharmaceutical industry companies comparison, stone medicine revenue and net profit are the topAmong them, in terms of net profit, Stone Pharmaceutical Group's first-quarter profit and the current "pharma brother" Hengrui Pharmaceuticals is not far awayTo date, The Stone Pharmaceutical Group has a market capitalisation of over HK$100 billionHowever, the market value of Hengrui Pharmaceuticals is now 423.85 billion yuan, more than four times that of Shipharma GroupAccording to incomplete statistics, the current A-share pharmaceutical and biological industry, the market value of more than 100 billion yuan of listed pharmaceutical companies a total of 7, in addition to Hengrui Pharmaceuticals and Stone Pharmaceutical Group, including Meirui Medical, Pharmaceutical Ming Kangde, Eyre Eye, Changchun Gaoxin, Zhifei Biological, Yunnan White MedicineThe total market value of Murray Medical: RMB336.686 billion
Murray Medical achieved revenue of RMB4,741 million and net profit of 1.313 billion yuan in the first quarter of 2020, up 21.39 percent and 30.58 percent year-on-year, respectivelyIt is reported that in the first quarter of this year, the company's life information product line significantly benefited, driving the overall performance of a small accelerationdata show that Murray Medical is mainly engaged in medical device research and development, manufacturing, marketing and services, always customer demand-oriented, committed to providing quality products and services to global medical institutions the total market value of the drug Mingkang : 172.972 billion yuan
In the first quarter of this year, Pharmaceutical Mingkang achieved revenue of 3.188 billion yuan, up 15.1% from a year earlier, of which china's laboratory services sector and the U.S laboratory services sector maintained rapid growth in revenue; according to the data, Pharmacobei Kant is an internationalleader open capability and technology platform for pharmaceutical and medical device companies worldwide to provide laboratory research and development and production services from drug discovery and development to marketization 　The total market value of the of Ayer Ophthalmology: RMB152.691 billion
Eyre Eye reported total operating income of RMB1,642 million, a decrease of 26.86% YoY, and net profit attributable to shareholders of listed companies was RMB079 million, down 73.41% YoY data show that Eyre ophthalmology is mainly engaged in various types of ophthalmology diagnosis and treatment, surgical services and medical optometrists The company, which went public in 2009, was one of the first 28 companies to go public on THE GEM Changchun high-tech total market value: 132.441 billion yuan
Changchun high-tech first quarter results In the first three months of the year, the company achieved revenue of RMB1,661 million, down 6% YoY, and realized net profit of RMB542 million, up 49% YoY public information shows that Changchun Gaoxin's main business for biopharmaceutical and traditional Chinese medicine research and development, production and sales, supplemented by real estate development, property management and real estate leasing business Zhifei Bio's total market value : 130.896 billion yuan
Zhifei Bio achieved revenue of 2.635 billion yuan in the first quarter of 2020, up 14.87 percent year-on-year, and net profit attributable to shareholders of listed companies was 516 million yuan, up 2.85 percent year-on-year data show that Zhifei Bio is a vaccine, biological products research and development, production, sales, promotion, distribution and import and export of a bio-high-tech enterprises 　Yunnan White Medicine total market value: 112.514 billion yuan
Yunnan White Pharmaceuticals achieved operating income of 7.743 billion yuan in the first quarter, up 10.53 percent year-on-year, and net profit attributable to shareholders of listed companies was 1.282 billion yuan, down 34.48 percent year-on-year data show that Yunnan white medicine is mainly divided into drugs, health products, Chinese medicine resources and pharmaceutical logistics four major plates, each plate is run independently, but also support each other, forming from the selection, planting, research and development, manufacturing to health products and services of the entire industrial chain market value system, the formation of three-product integration, multi-sector coordinated development of the economic ecosystem